RECRUITING

The Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis

Talk to us

Conditions

Atopic Dermatitis (AD)Atopic dermatitisEczemaBotox

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to understand cellular and molecular interactions in the skin of participants with mild-to-moderate AD, and how botulinum toxin alters these interactions.

Official Title

Pilot Study on Cellular and Molecular Impact of Neuroimmune Interactions in Atopic Dermatitis

Quick Facts

Study Start:2025-07-17
Study Completion:2026-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06928246

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Patients 18 years or older at time of consent
  2. * Mild-to-Moderate AD, defined as:
  3. * BSA ≤ 10%
  4. * IGA ≤ 3
  5. * No past biologic therapy
  6. * No systemic therapy for 3 months
  7. * No topical therapy for treatment of AD for 4 weeks
  8. * Patients 18 years or older at time of consent
  9. * Mild-to-Moderate AD, defined as:
  10. * BSA ≤ 10%
  11. * IGA ≤ 3
  12. * At least one patch of eczema of at least 5 cm in diameter
  13. * No past biologic therapy
  14. * No systemic therapy for 3 months
  15. * No topical therapy for treatment of AD for 4 weeks
  1. * Age less than 18 years old
  2. * Pregnant or breastfeeding
  3. * Has medical comorbidity such as end stage congestive heart failure or coagulopathy that is a relative contradiction to skin biopsy procedure
  4. * Has had prior exposure to biologic treatments or has had prior treatment with systemic non-biologics (e.g. methotrexate) within 12 weeks
  5. * Has used topical therapy for treatment of AD within 4 weeks
  6. * Patients enrolled in Phase 1
  7. * Age less than 18 years old
  8. * Pregnant or breastfeeding
  9. * Has medical comorbidity such as end stage congestive heart failure or coagulopathy that is a relative contradiction to skin biopsy procedure
  10. * Has had prior exposure to biologic treatments or has had prior treatment with systemic non-biologics (e.g. methotrexate) within 12 weeks
  11. * Has used topical therapy for treatment of AD within 4 weeks

Contacts and Locations

Study Contact

Charity Ruhl, LPN
CONTACT
4126472013
ruhlcl@upmc.edu
Anna Davis, MD
CONTACT
4126475633
davisa60@upmc.edu

Principal Investigator

Daniel Kaplan, MD, PhD
PRINCIPAL_INVESTIGATOR
University of Pittsburgh

Study Locations (Sites)

University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15213
United States
UPMC Department of Dermatology
Pittsburgh, Pennsylvania, 15213
United States

Collaborators and Investigators

Sponsor: Daniel Kaplan

  • Daniel Kaplan, MD, PhD, PRINCIPAL_INVESTIGATOR, University of Pittsburgh

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-07-17
Study Completion Date2026-01

Study Record Updates

Study Start Date2025-07-17
Study Completion Date2026-01

Terms related to this study

Keywords Provided by Researchers

  • Atopic dermatitis
  • Eczema
  • Botox

Additional Relevant MeSH Terms

  • Atopic Dermatitis (AD)